RU2001103131A - URATOXIDASE - Google Patents

URATOXIDASE

Info

Publication number
RU2001103131A
RU2001103131A RU2001103131/13A RU2001103131A RU2001103131A RU 2001103131 A RU2001103131 A RU 2001103131A RU 2001103131/13 A RU2001103131/13 A RU 2001103131/13A RU 2001103131 A RU2001103131 A RU 2001103131A RU 2001103131 A RU2001103131 A RU 2001103131A
Authority
RU
Russia
Prior art keywords
uricase
amino acids
protein
nucleic acid
acid molecule
Prior art date
Application number
RU2001103131/13A
Other languages
Russian (ru)
Other versions
RU2290439C2 (en
Inventor
Майкл ХЕРШФИЛД
Сьюзн Дж. КЕЛЛИ
Original Assignee
Дьюк Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дьюк Юниверсити filed Critical Дьюк Юниверсити
Publication of RU2001103131A publication Critical patent/RU2001103131A/en
Application granted granted Critical
Publication of RU2290439C2 publication Critical patent/RU2290439C2/en

Links

Claims (17)

1. Белок, содержащий рекомбинантный белок уриказы видов млекопитающих, который был модифицирован встраиванием одного или нескольких остатков лизина.1. A protein containing a recombinant uricase protein of a mammalian species that has been modified by the incorporation of one or more lysine residues. 2. Белок по п. 1, отличающийся тем, что указанный рекомбинантный белок является химерным белком из двух или нескольких аминокислотных последовательностей млекопитающих. 2. The protein of claim 1, wherein said recombinant protein is a chimeric protein of two or more mammalian amino acid sequences. 3. Белок по п. 2, отличающийся тем, что указанный рекомбинантный уриказный химерный белок включает 304 аминокислоты, причем первая состоящая из 225 аминокислот N-концевая часть указанных 304 аминокислот является аминокислотами 1-225 уриказы свиньи, а остальные 79 аминокислот из указанных 304 аминокислот являются аминокислотами 226-304 уриказы павиана. 3. The protein of claim 2, wherein said recombinant uricase chimeric protein comprises 304 amino acids, wherein the first 225-amino acid N-terminal portion of said 304 amino acids is 1-225 pig uricase amino acids and the remaining 79 amino acids from said 304 amino acids are amino acids 226-304 uricase baboon. 4. Белок по п. 2, отличающийся тем, что указанный рекомбинантный уриказный химерный белок включает 304 аминокислоты, причем первая состоящая из 288 аминокислот N-концевая часть указанных 304 аминокислот является аминокислотами 1-288 уриказы свиньи, а остальные 16 аминокислот из указанных 304 аминокислот являются аминокислотами 289-304 уриказы павиана. 4. The protein of claim 2, wherein said recombinant uricase chimeric protein comprises 304 amino acids, the first 288 amino acids of the N-terminal portion of the indicated 304 amino acids being amino acids 1-288 of the pig uricase, and the remaining 16 amino acids of the indicated 304 amino acids are amino acids 289-304 uricase baboon. 5. Рекомбинантный уриказный белок, выбранный из группы, состоящей из последовательностей SEI ID NO: 2, 4, 8, 9, 10 и 11. 5. Recombinant uricase protein selected from the group consisting of the sequences of SEI ID NO: 2, 4, 8, 9, 10, and 11. 6. Выделенная и очищенная молекула нуклеиновой кислоты, кодирующая рекомбинантную уриказу по п. 1. 6. The isolated and purified nucleic acid molecule encoding the recombinant uricase according to claim 1. 7. Выделенная и очищенная молекула нуклеиновой кислоты, кодирующая рекомбинантную уриказу по п. 3. 7. The isolated and purified nucleic acid molecule encoding the recombinant uricase according to claim 3. 8. Выделенная и очищенная молекула нуклеиновой кислоты, кодирующая рекомбинантную уриказу по п. 4. 8. The isolated and purified nucleic acid molecule encoding the recombinant uricase according to claim 4. 9. Выделенная и очищенная молекула нуклеиновой кислоты, кодирующая рекомбинантную уриказу по п. 5. 9. The isolated and purified nucleic acid molecule encoding the recombinant uricase according to claim 5. 10. Выделенная и очищенная молекула нуклеиновой кислоты по п. 9, имеющая последовательность нуклеотидов SEQ ID NO: 1. 10. The isolated and purified nucleic acid molecule according to claim 9, having the nucleotide sequence of SEQ ID NO: 1. 11. Выделенная и очищенная молекула нуклеиновой кислоты по п. 9, имеющая последовательность нуклеотидов SEQ ID NO: 3. 11. The isolated and purified nucleic acid molecule according to claim 9, having the nucleotide sequence of SEQ ID NO: 3. 12. Вектор, включающий молекулу нуклеиновой кислоты по п. 1. 12. A vector comprising a nucleic acid molecule according to claim 1. 13. Вектор, включающий молекулу нуклеиновой кислоты по п. 9. 13. A vector comprising a nucleic acid molecule according to claim 9. 14. Клетка-хозяин, включающая вектор по п. 12. 14. A host cell comprising the vector of claim 12. 15. Клетка-хозяин, включающая вектор по п. 13. 15. A host cell comprising the vector of claim 13. 16. Способ увеличения доступных не причиняющих вреда сайтов присоединения ПЭГ к уриказному белку, предусматривающий мутирование уриказного белка, посредством которого в него вводят, по меньшей мере, один остаток лизина. 16. A method of increasing available non-harmful sites of attachment of PEG to a uricase protein, comprising mutating the uricase protein, by means of which at least one lysine residue is introduced into it. 17. Способ увеличения доступных не причиняющих вреда сайтов присоединения ПЭГ к уриказному белку, предусматривающий мутирование уриказного белка, посредством которого в него вводят, по меньшей мере, один остаток лизина вместо аргинина. 17. A method of increasing the available non-harmful sites of attachment of PEG to a uricase protein, comprising mutating the uricase protein, by means of which at least one lysine residue is introduced into it instead of arginine.
RU2001103131/13A 1998-08-06 1999-08-05 Recombinant mammalian uricase protein for conjunction with peg, nucleic acid molecule encoding the same expression vector, methods for production abd uses thereof RU2290439C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9548998P 1998-08-06 1998-08-06
US60/095,489 1998-08-06

Publications (2)

Publication Number Publication Date
RU2001103131A true RU2001103131A (en) 2003-04-10
RU2290439C2 RU2290439C2 (en) 2006-12-27

Family

ID=22252247

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001103131/13A RU2290439C2 (en) 1998-08-06 1999-08-05 Recombinant mammalian uricase protein for conjunction with peg, nucleic acid molecule encoding the same expression vector, methods for production abd uses thereof

Country Status (23)

Country Link
US (1) US7056713B1 (en)
EP (2) EP2277998B1 (en)
JP (3) JP2002524053A (en)
KR (1) KR100841634B1 (en)
CN (2) CN1322243A (en)
AT (1) ATE483797T1 (en)
AU (1) AU766421B2 (en)
BR (1) BRPI9913360B8 (en)
CA (1) CA2337967C (en)
CY (1) CY1111001T1 (en)
CZ (1) CZ304223B6 (en)
DE (1) DE69942834D1 (en)
DK (1) DK1100880T3 (en)
ES (1) ES2352451T3 (en)
HK (3) HK1037214A1 (en)
HU (1) HU229774B1 (en)
IL (3) IL141221A0 (en)
NZ (1) NZ509633A (en)
PL (1) PL207369B1 (en)
PT (1) PT1100880E (en)
RU (1) RU2290439C2 (en)
WO (1) WO2000008196A2 (en)
ZA (1) ZA200100974B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2451074C2 (en) * 2005-04-11 2012-05-20 Савиент Фармасьютикалз, Инк. Alternative forms of urate oxidase and using them
US10139399B2 (en) 2009-06-25 2018-11-27 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2158923E (en) 1998-08-06 2013-06-04 Univ Duke Peg-urate oxidase conjugates and use thereof
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
RU2246318C2 (en) * 1998-08-06 2005-02-20 Маунтэн Вью Фармасьютикэлз, Инк. Uricase peg-conjugates and their applying
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
PL207369B1 (en) * 1998-08-06 2010-12-31 Univ Duke Urate oxidase
CN100371439C (en) * 2003-04-07 2008-02-27 北京双鹭药业股份有限公司 Preparation method of recombinant can diad urate oxidase
CN100334207C (en) * 2004-04-27 2007-08-29 杭州北斗生物技术有限公司 Process for preparing aspergillus flavus urate oxidase
BRPI0612942A2 (en) * 2005-04-11 2012-10-09 Savient Pharmaceuticals Inc variant form of urate oxidase and its use
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
AU2011257764B2 (en) * 2005-04-11 2012-04-05 Horizon Therapeutics Usa, Inc. A variant form of urate oxidase and use thereof
PL2013225T3 (en) * 2006-04-12 2015-06-30 Crealta Pharmaceuticals Llc Purification of proteins with cationic surfactant
CN101402688B (en) * 2008-11-18 2011-04-20 中国人民解放军军事医学科学院生物工程研究所 Fusion protein, encoding gene and uses thereof
AU2010229341B9 (en) 2009-03-24 2013-06-27 Meito Sangyo Co., Ltd. Improved type milk-clotting protease derived from a microorganism
CN102051348B (en) * 2009-10-27 2012-10-03 重庆富进生物医药有限公司 Humanized recombinant uricase and mutant thereof
RU2460793C2 (en) 2010-01-15 2012-09-10 Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) Method for producing l-amino acids with use of bacteria of enterobacteriaceae family
US8940861B2 (en) 2010-04-08 2015-01-27 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
CN102634492B (en) * 2011-02-14 2015-06-10 重庆富进生物医药有限公司 Polyethylene glycol dog source urate oxidase analogue, and preparation method and applications thereof
CN102757945B (en) * 2011-04-28 2015-03-18 杭州俊丰生物工程有限公司 Human urate oxidase protein and preparation method and polyethylene glycol composite thereof
CN102260653B (en) * 2011-06-30 2013-04-03 荣俊 Preparation and application method of PEG recombinant pig-human urate oxidase fusion protein
EP2986720B1 (en) * 2013-04-17 2017-09-06 Council of Scientific & Industrial Research Uricase mutants
CN103834623B (en) * 2014-02-11 2017-11-07 中国药科大学 People source urate oxidase with catalytic activity
CN104388467A (en) * 2014-10-27 2015-03-04 李长贵 Method for constructing spontaneous hyperuricemia mouse model and application of mouse model
CN107614007B (en) 2015-05-15 2022-03-25 免疫医疗有限责任公司 Improved uricase sequences and methods of treatment
CN106554948B (en) * 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 Saltant type uricase, the saltant type uricase of PEG modification and its application
CN108103079B (en) * 2017-06-20 2021-07-13 北京锦篮基因科技有限公司 Gene therapy medicine for hyperuricemia
CN109554376B (en) * 2018-11-13 2022-03-22 广西大学 Alkaline urate oxidase and application thereof in detection kit and reduction of uric acid in food
CN111088268B (en) * 2019-03-05 2022-08-02 北京锦篮基因科技有限公司 Gene therapy medicine for hyperuricemia
AU2020276510A1 (en) 2019-05-10 2021-12-16 Hangzhou Grand Biologic Pharmaceutical Inc. Polyethylene glycol-modified urate oxidase
CN112646790A (en) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 Improved uricase and methods for its use in treating hyperuricemia
CN111920942A (en) * 2020-08-24 2020-11-13 深圳前海鹰岗生物科技有限公司 Polymer microneedle for rapidly dissolving tophus and preparation method and application
CN114438048A (en) 2020-11-05 2022-05-06 重庆派金生物科技有限公司 Urate oxidase preparation and application thereof
CN114438047A (en) 2020-11-05 2022-05-06 重庆派金生物科技有限公司 Method for preparing polyethylene glycol modified urate oxidase
CN112852772A (en) * 2021-01-19 2021-05-28 中国科学院过程工程研究所 Urate oxidase based on intramolecular cross-linking and polyethylene glycol modification and preparation method thereof
CN112662640A (en) * 2021-01-28 2021-04-16 中国药科大学 Urate oxidase with catalytic activity
CN113244412B (en) * 2021-06-25 2021-10-26 深圳市瑞吉生物科技有限公司 Medicine for treating hyperuricemia or gout based on mRNA dosage form and preparation method thereof
AU2022340814A1 (en) * 2021-09-01 2024-02-15 Ginkgo Bioworks, Inc. Recombinant cells for treating diseases associated with uric acid and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (en)
US3613231A (en) 1969-07-25 1971-10-19 Paul F Pugh Method for manufacturing high voltage cable systems
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3126759A1 (en) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim SOLUBLE LIVER URICASE, METHOD FOR THE PRODUCTION AND USE THEREOF
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5075216A (en) 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5382518A (en) 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
WO1994019007A1 (en) 1993-02-16 1994-09-01 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
JPH10510516A (en) 1994-12-07 1998-10-13 ノボ ノルディスク アクティーゼルスカブ Polypeptides with reduced allergenicity
JPH09154581A (en) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd Substantially pure microorganism capable of producing uricase
CA2279986A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
RU2246318C2 (en) 1998-08-06 2005-02-20 Маунтэн Вью Фармасьютикэлз, Инк. Uricase peg-conjugates and their applying
PL207369B1 (en) * 1998-08-06 2010-12-31 Univ Duke Urate oxidase
PT2158923E (en) 1998-08-06 2013-06-04 Univ Duke Peg-urate oxidase conjugates and use thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2451074C2 (en) * 2005-04-11 2012-05-20 Савиент Фармасьютикалз, Инк. Alternative forms of urate oxidase and using them
RU2610680C2 (en) * 2005-04-11 2017-02-14 Криэлта Фармасьютикалз ЭлЭлСи Variant forms of urate oxidase and use thereof
RU2610680C9 (en) * 2005-04-11 2018-05-30 Криэлта Фармасьютикалз ЭлЭлСи Variant forms of urate oxidase and use thereof
US10160958B2 (en) 2005-04-11 2018-12-25 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US10731139B2 (en) 2005-04-11 2020-08-04 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US11345899B2 (en) 2005-04-11 2022-05-31 Horizon Therapeutics Usa, Inc. Variant forms of urate oxidase and use thereof
US10139399B2 (en) 2009-06-25 2018-11-27 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US10823727B2 (en) 2009-06-25 2020-11-03 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US11639927B2 (en) 2009-06-25 2023-05-02 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy

Similar Documents

Publication Publication Date Title
RU2001103131A (en) URATOXIDASE
CA2337967A1 (en) Recombinant uricase protein
Sluka et al. Importance of minor-groove contacts for the recognition of DNA by the binding domain of Hin recombinase
PL317722A1 (en) Sequences of synthetic leader peptides
EP0305488A4 (en) Mycobacterial recombinants and peptides
WO2004108938A3 (en) Peptide ligands of dendritic cells for nucleic acid vector targeting
AU7891498A (en) Flower organ-specific gene and its promoter sequence
KR100237126B1 (en) Rapid synthesis and screening of peptide mimetics
RU2000103824A (en) Adipocyte-Specific Protein Homologues
SE9402089D0 (en) Recombinant allergen, fragments thereof, corresponding recombinant DNA molecules, vectors and hosts containing the DNA molecules, diagnostic and therapeutic uses of said allergens and fragments
US20120107870A1 (en) Selective enzymatic amidation of c-terminal esters or acids of peptides
DE3485199D1 (en)
AU629430B2 (en) Bacterial collagenase gene
WO2002010384A1 (en) Genes encoding proteins capable of regenerating luciferin, recombinant dna and process for producing protein capable of regenerating luciferin
WO2000017232A3 (en) Regulatory protein from human keratinocytes
EP2167673B1 (en) Process for the conversion of c-terminal peptide esters or acids to amides employing subtilisin in the presence of ammonium salts
Stasiak et al. Peptides derived from α-hydroxymethylserine: Aspects of solid-phase synthesis
EP0959895A4 (en) Peptides responsive to antibodies against a consensus peptide of the cs4-cfa/i family proteins
WO2002010383A1 (en) Genes encoding proteins capable of regenerating luciferin, recombinant dna and process for producing protein capable of regenerating luciferin
Miura et al. Synthesis of a Fragment (Pentapeptide) of E. Coli Acyl Carrier Protein Apoprotein
WO2002022632A3 (en) Nucleotide sequences coding for the pknd gene
RU99127322A (en) PROTEINS CONNECTING TO SUGAROSE
CA2419038A1 (en) Nucleic acid and protein increasing expression levels under salt stress
Marczak et al. Practical approach to enzymatic resolution of Fmoc-and Boc-protected amino acid racemates
DE60021707D1 (en) BETA-PRIMEVEROSIDASE GEN